Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 4 5Phase NA 4Phase 2/3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1Classical hematology 1

Conditions

Stomach Neoplasms 1Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Duodenal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Rivaroxaban × Clear all
NCT06220123 2025-07-22

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 2 Completed
225 enrolled
Classical hematologyGynecologic

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

NCT03139487 2020-01-06

PRIORITY

Asan Medical Center

Phase 2 Unknown
176 enrolled
GastrointestinalSarcoma

Biliary Tract Neoplasms, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡